909708-65-2
909708-65-2
Chemical Structure
Liguzinediol
- CAS No.: 909708-65-2
- Formula:C8H12N2O2
- Molecular Weight:168.20
IUPAC Name: (3,6-dimethylpyrazine-2,5-diyl)dimethanol
InChIKey: DLCVYRQRINMKBM-UHFFFAOYSA-N
SMILES: OCC1=NC(=C(N=C1C)CO)C
Biological Activity: Liguzinediol is a Bcl-2 upregulator that exerts cardioprotective effects by upregulating Bcl-2, downregulating Bax and cleaved caspase-3, and inhibiting myocardial apoptosis, RAAS, oxidative stress, inflammation, and extracellular matrix remodeling. Liguzinediol can be used for research on heart failure and cardiac fibrosis[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Liguzinediol | Liguzinediol is a Bcl-2 upregulator that exerts cardioprotective effects by upregulating Bcl-2, downregulating Bax and cleaved caspase-3, and inhibiting myocardial apoptosis, RAAS, oxidative stress, inflammation, and extracellular matrix remodeling. Liguzinediol can be used for research on heart failure and cardiac fibrosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Li Y, et al. Liguzinediol improved the heart function and inhibited myocardial cell apoptosis in rats with heart failure. Acta pharmacologica Sinica. 2014 Oct;35(10):1257-64.
- [2]. Wu X, et al. Liguzinediol protects against cardiac fibrosis in rats in vivo and in vitro. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2016 May;80:260-267. [Content Brief]
- [3]. Chen Q, et al. The protective effects of liguzinediol on congestive heart failure induced by myocardial infarction and its relative mechanism. Chinese medicine. 2020;15:63. [Content Brief]
- [4]. You X, et al. Study on Pharmacokinetics of Liguzinediol and Four Metabolites in Rats by UFLC–MS/MS. Chromatographia 79, 703–710 (2016).
- [5]. Chen L, et al. The novel compound liguzinediol exerts positive inotropic effects in isolated rat heart via sarcoplasmic reticulum Ca2+ ATPase-dependent mechanism. Life sciences. 2012 Oct 05;91(11-12):402-408.
- [6]. Li S, et al. Liguzinediol Enhances the Inotropic Effect of Rat Hearts via Inhibition of Protein Phosphatase (PP1 and PP2A) Activities. Journal of cardiovascular pharmacology. 2017 Apr;69(4):236-244.
